D. Du

Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)

Edward S. Kim, J. Lee, J. Heymach, 2007 .

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

Edward S. Kim, J. Lee, A. Ryan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

E. Jonasch, C. Logothetis, H. Tran, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phenotypic Heterogeneity Analysis of APC-Mutant Colon Cancer by Proteomics and Phosphoproteomics Identifies RAI14 as a Key Prognostic Determinant in East Asians and Westerners

Yuan Li, Y. Shu, Xuyang Xia, 2023, Molecular & cellular proteomics : MCP.

A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC).

E. Jonasch, H. Tran, A. Zurita, 2009, Journal of Clinical Oncology.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

E. Jonasch, C. Logothetis, H. Tran, 2012 .